The Journal of Immunology, Vol 145, Issue 1 238-245, Copyright © 1990 by American Association of Immunologists

ARTICLES

Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down- regulated during cell differentiation

T Seya, T Hara, M Matsumoto and H Akedo
Department of Immunology, Center for Adult Diseases, Osaka, Japan.

Membrane cofactor protein (MCP) is a cell-associated regulatory molecule for C system with C3b/C4b binding and factor I-dependent cofactor activity. mAb were raised against MCP and amounts and distribution examined on normal human cells and cell lines. The mean quantity of MCP was 3000 to 7000 copies/cell in normal blood cells, except for E which have no MCP. Of note, PMN did not fully reveal all MCP sites until incubated for greater than 30 min at 37 degrees C. In most tumor cell lines, except for B cell lineages, expression of MCP increased by 2- to 8-fold in comparison with the normal cell counterparts. Strikingly, recombinant granulocyte CSF treatment of myeloid cell lines and hemin treatment of an erythroblastoid cell line, K562, led to a decrease of MCP to near normal levels. In contrast, C3b/C4b receptor (CR1) tended to increase with granulocyte-CSF treatment in several cell lines. We simultaneously determined levels of decay-accelerating factor (DAF) and CR1 in these tumor cells, and tested susceptibility to C3 deposition via activation of the alternative C pathway. Of 21 cell lines we examined, 14 lacked CR1 and two lacked DAF; none, however, lacked MCP. A slight amount of C3 deposition was observed in some myeloid cell lines and EBV-infected B cell lines. However, C3 deposition did not reflect a defect in the regulatory proteins. Tumor cells bearing MCP, lacking CR1 or DAF, and undergoing no C3 deposition, may escape C attack due to the compensatory effect of MCP in the absence of the other regulatory proteins. High expression of MCP provides a convenient means for tumor cells to block C attack and survive in blood stream. We favor the interpretation that MCP is up-regulated in association with certain malignant disorders, and that cell differentiation results in a switch from an MCP-dominant state to a CR1-dominant state.

This article has been cited by other articles:

				L. Lovkvist, H. Sjolinder, R. Wehelie, H. Aro, A. Norrby-Teglund, L. Plant, and A.-B. Jonsson CD46 Contributes to the Severity of Group A Streptococcal Infection Infect. Immun., September 1, 2008; 76(9): 3951 - 3958. [Abstract] [Full Text] [PDF]

				M. Takeda, M. Tahara, T. Hashiguchi, T. A. Sato, F. Jinnouchi, S. Ueki, S. Ohno, and Y. Yanagi A Human Lung Carcinoma Cell Line Supports Efficient Measles Virus Growth and Syncytium Formation via a SLAM- and CD46-Independent Mechanism J. Virol., November 1, 2007; 81(21): 12091 - 12096. [Abstract] [Full Text] [PDF]

				M. Shingai, T. Ebihara, N. A. Begum, A. Kato, T. Honma, K. Matsumoto, H. Saito, H. Ogura, M. Matsumoto, and T. Seya Differential Type I IFN-Inducing Abilities of Wild-Type versus Vaccine Strains of Measles Virus J. Immunol., November 1, 2007; 179(9): 6123 - 6133. [Abstract] [Full Text] [PDF]

				M. Takemoto, K. Yamanishi, and Y. Mori Human herpesvirus 7 infection increases the expression levels of CD46 and CD59 in target cells J. Gen. Virol., May 1, 2007; 88(5): 1415 - 1422. [Abstract] [Full Text] [PDF]

				F. Seki, M. Takeda, H. Minagawa, and Y. Yanagi Recombinant wild-type measles virus containing a single N481Y substitution in its haemagglutinin cannot use receptor CD46 as efficiently as that having the haemagglutinin of the Edmonston laboratory strain J. Gen. Virol., June 1, 2006; 87(6): 1643 - 1648. [Abstract] [Full Text] [PDF]

				F. Pichiorri, F. Trapasso, T. Palumbo, R. I. Aqeilan, A. Drusco, B. W. Blaser, D. Iliopoulos, M. A. Caligiuri, K. Huebner, and C. M. Croce Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35. Clin. Cancer Res., June 1, 2006; 12(11): 3494 - 3501. [Abstract] [Full Text] [PDF]

				J. L. Edwards and M. A. Apicella The Molecular Mechanisms Used by Neisseria gonorrhoeae To Initiate Infection Differ between Men and Women Clin. Microbiol. Rev., October 1, 2004; 17(4): 965 - 981. [Abstract] [Full Text] [PDF]

				R. Ohta, N. Kondor, N. Dohi, S. Tomlinson, M. Imai, V. M. Holers, H. Okada, and N. Okada Mouse Complement Receptor-Related Gene y/p65-Neutralized Tumor Vaccine Induces Antitumor Activity In Vivo J. Immunol., July 1, 2004; 173(1): 205 - 213. [Abstract] [Full Text] [PDF]

				F. Santoro, H. L. Greenstone, A. Insinga, M. K. Liszewski, J. P. Atkinson, P. Lusso, and E. A. Berger Interaction of Glycoprotein H of Human Herpesvirus 6 with the Cellular Receptor CD46 J. Biol. Chem., July 3, 2003; 278(28): 25964 - 25969. [Abstract] [Full Text] [PDF]

				H. L. Greenstone, F. Santoro, P. Lusso, and E. A. Berger Human Herpesvirus 6 and Measles Virus Employ Distinct CD46 Domains for Receptor Function J. Biol. Chem., October 11, 2002; 277(42): 39112 - 39118. [Abstract] [Full Text] [PDF]

				K. Hashimoto, N. Ono, H. Tatsuo, H. Minagawa, M. Takeda, K. Takeuchi, and Y. Yanagi SLAM (CD150)-Independent Measles Virus Entry as Revealed by Recombinant Virus Expressing Green Fluorescent Protein J. Virol., June 5, 2002; 76(13): 6743 - 6749. [Abstract] [Full Text] [PDF]

				D. M. Tobiason and H. S. Seifert Inverse relationship between pilus-mediated gonococcal adherence and surface expression of the pilus receptor, CD46 Microbiology, August 1, 2001; 147(8): 2333 - 2340. [Abstract] [Full Text] [PDF]

				M. Kurita-Taniguchi, A. Fukui, K. Hazeki, A. Hirano, S. Tsuji, M. Matsumoto, M. Watanabe, S. Ueda, and T. Seya Functional Modulation of Human Macrophages Through CD46 (Measles Virus Receptor): Production of IL-12 p40 and Nitric Oxide in Association with Recruitment of Protein-Tyrosine Phosphatase SHP-1 to CD46 J. Immunol., November 1, 2000; 165(9): 5143 - 5152. [Abstract] [Full Text] [PDF]

				J. L. Edwards, J. Q. Shao, K. A. Ault, and M. A. Apicella Neisseria gonorrhoeae Elicits Membrane Ruffling and Cytoskeletal Rearrangements upon Infection of Primary Human Endocervical and Ectocervical Cells Infect. Immun., September 1, 2000; 68(9): 5354 - 5363. [Abstract] [Full Text] [PDF]

				S. Chen, T. Caragine, N.-K. V. Cheung, and S. Tomlinson CD59 Expressed on a Tumor Cell Surface Modulates Decay-accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma Cancer Res., June 1, 2000; 60(11): 3013 - 3018. [Abstract] [Full Text] [PDF]

				M. J. Corey, R. J. Kinders, C. M. Poduje, C. L. Bruce, H. Rowley, L. G. Brown, G. M. Hass, and R. L. Vessella Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis J. Biol. Chem., April 21, 2000; 275(17): 12917 - 12925. [Abstract] [Full Text] [PDF]

				S. Kikkawa, M. Matsumoto, T. Sasaki, M. Nishiguchi, K. Tanaka, K. Toyoshima, and T. Seya Complement Activation in Mycoplasma fermentans-Induced Mycoplasma Clearance from Infected Cells: Probing of the Organism with Monoclonal Antibodies against M161Ag Infect. Immun., March 1, 2000; 68(3): 1672 - 1680. [Abstract] [Full Text] [PDF]

				S. Chen, T. Caragine, N.-K. V. Cheung, and S. Tomlinson Surface Antigen Expression and Complement Susceptibility of Differentiated Neuroblastoma Clones Am. J. Pathol., March 1, 2000; 156(3): 1085 - 1091. [Abstract] [Full Text] [PDF]

				X. Wu, N. Okada, H. Momota, R. F. Irie, and H. Okada Complement-Mediated Anti-HIV-1 Effect Induced by Human IgM Monoclonal Antibody Against Ganglioside GM2 J. Immunol., January 1, 1999; 162(1): 533 - 539. [Abstract] [Full Text] [PDF]

				V. T. Blok, M. R. Daha, O. Tijsma, C. L. Harris, B. P. Morgan, G. J. Fleuren, and A. Gorter A Bispecific Monoclonal Antibody Directed Against Both the Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 Enhances C3 Deposition and Tumor Cell Lysis by Complement J. Immunol., April 1, 1998; 160(7): 3437 - 3443. [Abstract] [Full Text] [PDF]

				Y. Doi, M. Kurita, M. Matsumoto, T. Kondo, T. Noda, S. Tsukita, S. Tsukita, and T. Seya Moesin Is Not a Receptor for Measles Virus Entry into Mouse Embryonic Stem Cells J. Virol., February 1, 1998; 72(2): 1586 - 1592. [Abstract] [Full Text] [PDF]

				K. Iwata, T. Seya, Y. Yanagi, J. M. Pesando, P. M. Johnson, M. Okabe, S. Ueda, H. Ariga, and S. Nagasawa Diversity of Sites for Measles Virus Binding and for Inactivation of Complement C3b and C4b on Membrane Cofactor Protein CD46 J. Biol. Chem., June 23, 1995; 270(25): 15148 - 15152. [Abstract] [Full Text] [PDF]